Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT ID: NCT03486938

Last Updated: 2024-05-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 164 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-13
• Study Completion Date: 2022-11-02

Brief Summary

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).

Conditions

Mild Cognitive Impairment; Prodromal Alzheimer's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo Oral Tablet

Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo Oral Tablet

Intervention Type: DRUG

Placebo oral tablet

AGB101 220 mg tablet

Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.

Group Type: EXPERIMENTAL

AGB101 220 mg tablet

Intervention Type: DRUG

220 mg AGB101 active compound

Interventions

Placebo Oral Tablet

Placebo oral tablet

Intervention Type: DRUG

AGB101 220 mg tablet

220 mg AGB101 active compound

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects between 55 and 85 years old (inclusive) in good general health:

1. Willing and able to consent and participate for the duration of the study

2. Have eighth-grade education or good work history sufficient to exclude mental retardation

3. Have visual and auditory acuity adequate for neuropsychological testing

4. Have proficient fluency of the native local language to participate in all the neuropsychological test assessments

2. Have a study partner who has sufficient contact with the subject to be able to provide assessment of memory changes, who can accompany the subject to all the clinic visits for the duration of each visit, and who is able to provide an independent evaluation of the subject's functioning

3. Have MCI due to AD as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria:

1. MMSE scores between 24 and 30 (inclusive; exceptions may be made for subjects with <8 years of education at the discretion of the sponsor)

2. A memory complaint reported by the subject or his/her study partner

3. Evidence of lower memory performance based on delayed recall in the International Shopping List Test (ISLT)

4. A clinical dementia rating (CDR) score of 0.5 with a memory box score of ≥0.5

5. Essentially preserved activities of daily living

6. Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out)

4. Permitted medications:

1. With potential pro-cognitive effects, such as cholinesterase inhibitors and memantine, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study; estrogen replacement therapy, Ginkgo biloba, and vitamin E must be at a stable dose for ≥4 weeks prior to screening and remain stable throughout the study

2. Other psychotropics, such as antidepressants and antipsychotics, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study

5. Willing and able to undergo imaging procedures:

1. A Positron Emission Tomography (PET) scan with Florbetaben(an 18F isotope diagnostic agent) or documented evidence of an amyloid positive PET scan.

The Florbetaben scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques.

2. Repeated MRI scans (3 Tesla) with no contraindications to MRI. MRI scan results are consistent with the diagnosis of amnestic MCI due to Alzheimer's disease with no clinically significant findings of non-AD pathology that could account for the observed cognitive impairment.

6. Willing to allow collection of blood for apolipoprotein E (ApoE) genotyping.

Exclusion Criteria

1. Use of anticonvulsant medications or excluded psychotropic medications within 3 months prior to the baseline visit

2. Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study.

Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening.

3. History of hypersensitivity or lack of tolerability to AGB101 (levetiracetam)

4. Severe renal impairment (creatinine clearance of <30 mL/minute) or undergoing hemodialysis

5. Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder (lifetime history; infant febrile seizures are not exclusionary), subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities

6. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body

7. Diagnosis of major depression or bipolar disorder, as described in the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed (DSM-5), within the past 3 years.

Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The geriatric depression scale (long form score >9 suggests depression) results should be reviewed by the investigator to assist in this determination.

8. Modified Hachinski Ischemic Scale (HIS) score >4

9. History of schizophrenia (DSM-5 criteria)

10. History of alcohol or substance abuse or dependence within the past 3 years (DSM-5 criteria)

11. Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol requirements.

12. Clinically significant abnormalities in B12 or thyroid function test that might interfere with the study.

A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study.

13. Residence in a skilled nursing facility. Individuals in independent living communities, assisted living facilities, residential care facilities, or continuing care communities are eligible provided they engage in a sufficient spectrum of activity to permit assessment of all 6 domains contributing to the CDR-SB. Individuals in these facilities must also have a caregiver who has the ability to observe the subject during the study and can participate in clinical evaluations.

14. Any use of excluded medications (e.g., antiepileptics, certain antidepressants or antipsychotics, antihistamines with anticholinergic properties, opiates)

15. Participation in clinical studies using the ISLT, Behavioral Pattern Separation (BPS-O) task, or the trail making test (A, B) within 1 month of screening

16. Female subjects must not be pregnant, lactating, or of childbearing potential (i.e., they must be 2 years post menopause or surgically sterile)

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

AgeneBio

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Mohs, PhD

Role: PRINCIPAL_INVESTIGATOR

AgeneBio

Sharon Rosenzweig-Lipson, PhD

Role: STUDY_DIRECTOR

AgeneBio

Russell Barton, MS

Role: STUDY_DIRECTOR

AgeneBio

Locations

Banner Alzheimer's Institute

Phoenix, Arizona, United States

Senior Clinical Trials, Inc.

Laguna Hills, California, United States

Excell Research Inc

Oceanside, California, United States

The Mile High Research Center

Denver, Colorado, United States

Boynton Beach Medical Research Institite

Boynton Beach, Florida, United States

Brain Matters Research

Delray Beach, Florida, United States

MD Clinical

Hallandale, Florida, United States

Miami Jewish Health

Miami, Florida, United States

Bioclinica Research

Orlando, Florida, United States

IMIC Research

Palmetto Bay, Florida, United States

The Roskamp Institute, Inc

Sarasota, Florida, United States

Brain Matters Research

Stuart, Florida, United States

NeuroStudies.net, LLC

Decatur, Georgia, United States

Great Lakes Clinical Trials

Chicago, Illinois, United States

Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

Memory Center/Hattiesburg Clinic

Hattiesburg, Mississippi, United States

Clinical Research Professionals

Chesterfield, Missouri, United States

The NeuroCognitive Institute

Mount Arlington, New Jersey, United States

Global Medical Institutes LLC; Princeton Medical Institute

Princeton, New Jersey, United States

Neurology Specialist of Monmouth County, PA

West Long Branch, New Jersey, United States

Neurological Associates of Albany PC

Albany, New York, United States

Richmond Behavioral Associates

Staten Island, New York, United States

Clinical Biotechnology Research Institute at RSFH

Charleston, South Carolina, United States

Toronto Memory Program

Toronto, Ontario, Canada

Countries

United States; Canada

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

R56AG055416

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01AG048349

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01AG061091

Identifier Type: NIH

Identifier Source: secondary_id

View Link

AGB101 MCD

Identifier Type: -

Identifier Source: org_study_id